<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Fowler Brewer | Activity</title>
	<link>https://www.catswannabecats.com/members/chestcall25/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/chestcall25/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Fowler Brewer.</description>
	<lastBuildDate>Mon, 06 Jul 2026 08:03:58 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">757b47ebad845df90cfc73a17fe8fcb8</guid>
				<title>Fowler Brewer posted an update: Neurosarcoidosis is a rare systemic disorder that can affect [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/22123/</link>
				<pubDate>Sat, 07 Jun 2025 08:11:17 -0400</pubDate>

									<content:encoded><![CDATA[<p>Neurosarcoidosis is a rare systemic disorder that can affect the eye and other organs, including the central nervous system. Neurosarcoidosis infiltrating the optic nerve presenting as central retinal vein occlusion combined with artery ischaemia has not been reported in the literature previously. We describe a Chinese patient presenting with&hellip;<span class="activity-read-more" id="activity-read-more-22123"><a href="https://www.catswannabecats.com/activity/p/22123/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">12ca1ddc64c24d49a0adf832dc5f3adc</guid>
				<title>Fowler Brewer posted an update: Subcutaneous daratumumab (DARA SC; daratumumab co-formulated [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/2957/</link>
				<pubDate>Sat, 31 May 2025 09:38:06 -0400</pubDate>

									<content:encoded><![CDATA[<p>Subcutaneous daratumumab (DARA SC; daratumumab co-formulated with recombinant human hyaluronidase PH20) is administered in ~ 5 min and demonstrates safety and efficacy comparable to intravenous daratumumab, with low infusion-related reaction (IRR) rates in global populations. This open-label, multicenter, phase 1 study is the first evaluation of&hellip;<span class="activity-read-more" id="activity-read-more-2957"><a href="https://www.catswannabecats.com/activity/p/2957/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d05f0bb8c5d794e4f11ded0ea49d7b87</guid>
				<title>Fowler Brewer became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/2869/</link>
				<pubDate>Sat, 31 May 2025 09:27:22 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>